Lv6
2060 积分 2020-11-06 加入
NEJM at ESC — Asundexian versus Apixaban in Patients with Atrial Fibrillation
1年前
已完结
Asundexian versus Apixaban in Patients with Atrial Fibrillation
1年前
已完结
Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program
1年前
已完结
A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens
1年前
已完结
Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics
1年前
已完结
Rescuing the Last-Line Polymyxins: Achievements and Challenges
1年前
已完结
Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road
1年前
已完结
Treatment Strategies of Colistin Resistance Acinetobacter baumannii Infections
1年前
已完结
Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii
1年前
已完结
In vitroactivity of rifabutin against 293 contemporary carbapenem-resistantAcinetobacter baumanniiclinical isolates and characterization of rifabutin mode of action and resistance mechanisms
1年前
已完结
皖公网安备34019202002308
